Pregabalin for the treatment of generalized anxiety disorder;Prégabaline dans le traitement des troubles anxieux généralisés

Annals of Pharmacotherapy

Volumn 46, Issue 3, 2012, Pages 424-429

  Wensel, Terri M ^a   Powe, Krystal W ^b   Cates, Marshall E ^a  

^a SAMFORD UNIVERSITY   (United States)

^b Wal Mart Stores Inc   (United States)

Author keywords

Antianxiety agents; Anxiety disorders; Pregabalin

Indexed keywords

ALPRAZOLAM; LORAZEPAM; PLACEBO; PREGABALIN; VENLAFAXINE;

ANXIETY; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HEADACHE; HUMAN; MEDLINE; PRIORITY JOURNAL; PSYCHOSOMATICS; RELAPSE; REVIEW; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; XEROSTOMIA;

ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANXIETY DISORDERS; DIZZINESS; GAMMA-AMINOBUTYRIC ACID; HUMANS;

EID: 84858024917     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q405     Document Type: Review

References (17)

1. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006;368: 2156-66. DOI 10.1016/S0140-6736(06)69865-6
2. Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry 2009;70(suppl 2):4-9.
3. Simon NM. Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse. J Clin Psychia- try 2009;70(suppl 2):10-14.
4. Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 2009;23:103-20. DOI 10.2165/00023210-200923020-00002
5. Davidson JRT. First-line pharmacotherapy approaches for generalized anx- iety disorder. J Clin Psychiatry 2009;70(suppl 2):25-31.
6. Pollack MH. Refractory generalized anxiety disorder. J Clin Psychiatry 2009;70(suppl 2):32-38.
7. Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr 2004;9:716-23.
8. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007;27:263-72. DOI 10.1097/jcp.0b013e318059361a
9. Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005;39:2029-37. DOI 10.1345/aph.1G078
10. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anx- iety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160:533-40.
11. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double- blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23:240-9.
12. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, place- bo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62:1022-30.
13. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-con-trolled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005;25:151-8.
14. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a6week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006;67: 771-82.
15. Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and ven- lafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009;24:87-96. DOI 10.1097/YIC.0b013e32831d7980
16. Feltner D, Wittchen H, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008;23:18-28. DOI 10.1097/YIC.0b013e3282f0f0d7
17. Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disor- der. Br J Psychiatry 2008;193:389-94. DOI 10.1192/bjp.bp.107.037788